SIRT6-PAI-1 axis is a promising therapeutic target in aging-related bone metabolic disruption

Sci Rep. 2023 May 17;13(1):7991. doi: 10.1038/s41598-023-33297-7.

Abstract

The mechanistic regulation of bone mass in aged animals is poorly understood. In this study, we examined the role of SIRT6, a longevity-associated factor, in osteocytes, using mice lacking Sirt6 in Dmp-1-expressing cells (cKO mice) and the MLO-Y4 osteocyte-like cell line. cKO mice exhibited increased osteocytic expression of Sost, Fgf23 and senescence inducing gene Pai-1 and the senescence markers p16 and Il-6, decreased serum phosphate levels, and low-turnover osteopenia. The cKO phenotype was reversed in mice that were a cross of PAI-1-null mice with cKO mice. Furthermore, senescence induction in MLO-Y4 cells increased the Fgf23 and Sost mRNA expression. Sirt6 knockout and senescence induction increased HIF-1α binding to the Fgf23 enhancer sequence. Bone mass and serum phosphate levels were higher in PAI-1-null aged mice than in wild-type mice. Therefore, SIRT6 agonists or PAI-1 inhibitors may be promising therapeutic options for aging-related bone metabolism disruptions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Mice
  • Osteocytes / metabolism
  • Phosphates / metabolism
  • Plasminogen Activator Inhibitor 1* / genetics
  • Plasminogen Activator Inhibitor 1* / metabolism
  • Sirtuins* / genetics
  • Sirtuins* / metabolism

Substances

  • Phosphates
  • Plasminogen Activator Inhibitor 1
  • Sirt6 protein, mouse
  • Sirtuins
  • Serpine2 protein, mouse